查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553557

乳癌治疗市场规模、份额、趋势分析报告：按治疗、最终用途、地区和细分市场预测，2024-2030 年

Breast Adenocarcinoma Treatment Market Size, Share & Trends Analysis Report By Treatment (Chemotherapy, Targeted Therapy), By End Use (Hospitals, Specialty Clinics), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

乳癌治疗市场的成长与趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球乳癌治疗市场规模将达到428.7亿美元，2024年至2030年复合年增长率为9.1%。

这种增长主要是由治疗技术的进步、乳癌盛行率的增加以及对个人化医疗的日益关注所推动的。根据美国乳癌基金会的数据，美国八分之一的女性在一生中会被诊断出罹患乳癌。到 2024 年，估计将有 310,720 名女性和 2,800 名男性被诊断出患有侵袭性乳癌。在最早的局部阶段诊断出的乳癌的五年相对存活率为 99%。近年来，早期检测和治疗的进步显着提高了存活率，目前美国有超过 400 万名乳癌倖存者。

乳癌是乳癌的一种常见形式，目前正在透过多种创新疗法来治疗，包括标标靶治疗、免疫疗法和荷尔蒙疗法。市场规模的扩大归因于新药和新治疗方法的不断开拓，提高了治疗效果并改善了患者预后。此外，人们对乳癌的认识不断提高，以及早期检测的重要性也促使对先进治疗方案的需求不断增长。

全球乳癌负担日益增加，加上人口老化和发病率上升，也推动了市场扩张。随着越来越多的患者寻求先进的治疗方法以及医疗保健系统对最尖端科技的投资，乳癌治疗市场预计将显着成长。精准医学的技术进步，例如基因组分析和生物标记识别，正在实现更个人化的治疗方法。这些创新使癌细胞能够更有效地被靶向，同时最大限度地减少副作用，并改善整体患者体验。此外，正在进行的研究和临床试验可能会引入新的治疗方法和联合治疗，这可能会进一步推动市场成长。

乳癌治疗市场报告亮点

  • 2023年，标靶治疗领域占最大份额，达27.6%。这一优势反映了向更精确、更有效的治疗方法的转变，并凸显了标靶治疗在乳癌治疗中的变革性影响。
  • 医院板块占比最大，2023年将超过60.0%。这种增长主要是由于乳癌的高盛行率，推动了对医院治疗的巨大需求。
  • 市场上的一些知名企业包括默克公司、百时美施贵宝公司、协和麒麟公司、卫材公司、赛诺菲公司、辉瑞公司、Astra Zeneca、诺华公司、礼来公司和罗氏公司。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章乳癌治疗市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 乳癌治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • COVID-19 的影响

第四章全球乳癌治疗市场：依治疗分类的估计与趋势分析

  • 全球乳癌治疗市场：治疗仪表板
  • 全球乳癌治疗市场：治疗变异分析
  • 全球乳癌治疗市场（按治疗方式）
  • 化疗
  • 标靶治疗
  • 荷尔蒙疗法
  • 免疫疗法
  • 放射治疗
  • 其他的

第五章乳癌治疗市场：依最终用途分类的估计与趋势分析

  • 全球乳癌治疗市场：最终用途仪表板
  • 全球乳癌治疗市场：最终用途变化分析
  • 全球乳癌治疗市场（按最终用途）
  • 医院
  • 专科诊所
  • 其他的

第六章乳癌治疗市场：按地区、治疗、最终用途进行估计和趋势分析。

  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东/非洲

第七章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争对手分类
  • 供应商情况
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023年主要企业热图分析
  • 公司简介
    • Merck &Co
    • Bristol Myers Squiib
    • Kyowa Kirin
    • Eisai Co.Ltd
    • Sanofi
    • Pfizer Inc
    • AstraZeneca
    • Novartis AG
    • Eli Lilly and Company
    • F. Hoffmann La Roche AG
Product Code: GVR-4-68040-425-7

Breast Adenocarcinoma Treatment Market Growth & Trends:

The global breast adenocarcinoma treatment market size is expected to reach USD 42.87 billion by 2030 and is projected to grow at a CAGR of 9.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. This growth is significantly driven by the advancements in treatment technologies, the increasing prevalence of breast adenocarcinoma, and a growing focus on personalized medicine. According to the National Breast Cancer Foundation, in the U.S., 1 in 8 women will be diagnosed with breast cancer during their lifetime. For 2024, an estimated 310,720 women and 2,800 men are expected to be diagnosed with invasive breast cancer. The 5-year relative survival rate for breast cancer diagnosed at its earliest, localized stage is 99%. Advances in early detection and treatment have markedly improved survival rates in recent years, resulting in over 4 million breast cancer survivors currently living in the U.S.

Breast adenocarcinoma, a common form of breast cancer, is being addressed through a range of innovative treatments that include targeted therapies, immunotherapies, and hormonal therapies. The rise in market size can be attributed to the continual development of new drugs and therapies that enhance treatment efficacy and improve patient outcomes. In addition, the increasing awareness of breast cancer and the importance of early detection are contributing to a higher demand for advanced treatment options.

The increasing global burden of breast cancer, coupled with an aging population and rising incidence rates, is also fueling market expansion. As more patients seek advanced treatment options and healthcare systems invest in cutting-edge technologies, the market for breast adenocarcinoma treatments is set to grow significantly. Technological advancements in precision medicine, such as genomic profiling and biomarker identification, are enabling more personalized treatment approaches. These innovations allow for more effective targeting of cancer cells while minimizing side effects, thus enhancing the overall patient experience. Furthermore, ongoing research and clinical trials are likely to introduce novel therapies and combination treatments that could further drive market growth.

Breast Adenocarcinoma Treatment Market Report Highlights:

  • The targeted therapy segment held the largest share of 27.6 % in 2023. This prominence underscores the transformative impact of targeted therapies on breast cancer treatment, reflecting a shift towards more precise and effective treatment modalities.
  • The hospitals segment held the largest share of more than 60.0% in 2023. This growth is largely due to the high prevalence of breast cancer, which drives significant demand for hospital-based treatments.
  • Some of the prominent players in market are Merck & Co; Bristol Myers Squibb; Kyowa Kirin; Eisai Co. Ltd; Sanofi; Pfizer Inc; AstraZeneca; Novartis AG; Eli Lilly and Company; F. Hoffmann La Roche AG

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Treatment
    • 1.1.2. End Use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
    • 1.6.3. Volume price analysis (Model 2)
    • 1.6.4. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Outlook
    • 2.2.2. End Use Outlook
    • 2.2.3. Regional Outlook
  • 2.3. Competitive Insights

Chapter 3. Breast Adenocarcinoma Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Rising Prevalence of Breast Cancer
      • 3.2.1.2. Advancements In Treatment Modalities
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Stringent Regulation And Approvals
      • 3.2.2.2. High Cost of Treatments
  • 3.3. Breast Adenocarcinoma Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. COVID-19 Impact

Chapter 4. Global Breast Adenocarcinoma Treatment Market: Treatment Estimates & Trend Analysis

  • 4.1. Global Breast Adenocarcinoma Treatment Market: Treatment Dashboard
  • 4.2. Global Breast Adenocarcinoma Treatment Market: Treatment Movement Analysis
  • 4.3. Global Breast Adenocarcinoma Treatment Market, Treatment
  • 4.4. Chemotherapy
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
  • 4.5. Targeted Therapy
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
  • 4.6. Hormonal Therapy
    • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)
  • 4.7. Immunotherapy
    • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Billion)
  • 4.8. Radiation Therapy
    • 4.8.1. Market estimates and forecast 2018 to 2030 (USD Billion)
  • 4.9. Other
    • 4.9.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 5. Breast Adenocarcinoma Treatment Market: End Use Estimates & Trend Analysis

  • 5.1. Global Breast Adenocarcinoma Treatment Market: End Use Dashboard
  • 5.2. Global Breast Adenocarcinoma Treatment Market: End Use Movement Analysis
  • 5.3. Global Breast Adenocarcinoma Treatment Market, End Use
  • 5.4. Hospitals
    • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
  • 5.5. Specialty Clinics
    • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
  • 5.6. Others
    • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 6. Breast Adenocarcinoma Treatment Market: Regional Estimates & Trend Analysis, By Treatment, and By End Use.

  • 6.1. Regional Market Dashboard
  • 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.3. North America
    • 6.3.1. U.S.
      • 6.3.1.1. Key country dynamics
      • 6.3.1.2. Regulatory framework/ reimbursement structure
      • 6.3.1.3. Competitive scenario
      • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.3.2. Canada
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Regulatory framework/ reimbursement structure
      • 6.3.2.3. Competitive scenario
      • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.3.3. Mexico
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Regulatory framework/ reimbursement structure
      • 6.3.3.3. Competitive scenario
      • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Key country dynamics
      • 6.4.1.2. Regulatory framework/ reimbursement structure
      • 6.4.1.3. Competitive scenario
      • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.2. Germany
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Regulatory framework/ reimbursement structure
      • 6.4.2.3. Competitive scenario
      • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.3. France
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Regulatory framework/ reimbursement structure
      • 6.4.3.3. Competitive scenario
      • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.4. Italy
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Regulatory framework/ reimbursement structure
      • 6.4.4.3. Competitive scenario
      • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.5. Spain
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Regulatory framework/ reimbursement structure
      • 6.4.5.3. Competitive scenario
      • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.6. Norway
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Regulatory framework/ reimbursement structure
      • 6.4.6.3. Competitive scenario
      • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.7. Sweden
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Regulatory framework/ reimbursement structure
      • 6.4.7.3. Competitive scenario
      • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.4.8. Denmark
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Regulatory framework/ reimbursement structure
      • 6.4.8.3. Competitive scenario
      • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.2. China
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.3. India
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.4. Australia
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Regulatory framework/ reimbursement structure
      • 6.5.4.3. Competitive scenario
      • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.5. South Korea
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Regulatory framework/ reimbursement structure
      • 6.5.5.3. Competitive scenario
      • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.5.6. Singapore
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Regulatory framework/ reimbursement structure
      • 6.5.6.3. Competitive scenario
      • 6.5.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.6.2. Argentina
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7. MEA
    • 6.7.1. South Africa
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.2. Saudi Arabia
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.3. UAE
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
    • 6.7.4. Kuwait
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments and Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
    • 7.3.1. List of key distributors and channel partners
    • 7.3.2. Key customers
    • 7.3.3. Key company heat map analysis, 2023
  • 7.4. Company Profiles
    • 7.4.1. Merck & Co
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Product benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Bristol Myers Squiib
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Product benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Kyowa Kirin
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Product benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Eisai Co.Ltd
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Sanofi
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Pfizer Inc
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. AstraZeneca
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Novartis AG
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. Eli Lilly and Company
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. F. Hoffmann La Roche AG
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 3 North America Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 4 North America Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 5 U.S. Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 6 U.S. Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 7 Canada Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 8 Canada Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 9 Europe Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 10 Europe Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 11 Europe Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 12 Germany Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 13 Germany Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 14 UK Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 15 UK Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 16 France Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 17 France Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 18 Italy Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 19 Italy Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 20 Spain Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 21 Spain Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 22 Denmark Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 23 Denmark Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 24 Sweden Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 25 Sweden Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 26 Norway Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 27 Norway Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 28 Asia Pacific Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 29 Asia Pacific Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 30 Asia Pacific Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 31 China Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 32 China Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 33 Japan Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 34 Japan Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 35 India Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 36 India Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 37 South Korea Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 38 South Korea Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 39 South Korea Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 40 Australia Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 41 Australia Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 42 Thailand Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 43 Thailand Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 44 Latin America Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 45 Latin America Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 46 Latin America Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 47 Brazil Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 48 Brazil Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 49 Mexico Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 50 Mexico Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 51 Argentina Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 52 Argentina Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 53 MEA Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
  • Table 54 MEA Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 55 MEA Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 56 South Africa Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 57 South Africa Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 58 Saudi Arabia Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 59 Saudi Arabia Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 60 UAE Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 61 UAE Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
  • Table 62 Kuwait Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 63 Kuwait Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
  • Table 64 Kuwait Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Breast Adenocarcinoma Treatment Market: Market Outlook
  • Fig. 9 Breast Adenocarcinoma Treatment Competitive Insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Breast Adenocarcinoma Treatment Market Driver Impact
  • Fig. 15 Breast Adenocarcinoma Treatment Market Restraint Impact
  • Fig. 16 Breast Adenocarcinoma Treatment Market Strategic Initiatives Analysis
  • Fig. 17 Breast Adenocarcinoma Treatment Market: Treatment Movement Analysis
  • Fig. 18 Breast Adenocarcinoma Treatment Market: Treatment Outlook And Key Takeaways
  • Fig. 19 Chemotherapy market estimates and forecast, 2018 - 2030
  • Fig. 20 Targeted therapy market estimates and forecast, 2018 - 2030
  • Fig. 21 Hormonal therapy market estimates and forecast, 2018 - 2030
  • Fig. 22 Immunotherapy market estimates and forecast, 2018 - 2030
  • Fig. 23 Radiation therapy market estimates and forecast, 2018 - 2030
  • Fig. 24 Other market estimates and forecast, 2018 - 2030
  • Fig. 25 Breast Adenocarcinoma Treatment Market: End Use Movement Analysis
  • Fig. 26 Breast Adenocarcinoma Treatment Market: End Use Outlook And Key Takeaways
  • Fig. 27 Hospitals market estimates and forecast, 2018 - 2030
  • Fig. 28 Specialty clinics market estimates and forecast, 2018 - 2030
  • Fig. 29 Global Breast Adenocarcinoma Treatment Market: Regional Movement Analysis
  • Fig. 30 Global Breast Adenocarcinoma Treatment Market: Regional Outlook And Key Takeaways
  • Fig. 31 Global Breast Adenocarcinoma Treatment market share and leading companies
  • Fig. 32 North America: SWOT
  • Fig. 33 Europe SWOT
  • Fig. 34 Asia Pacific SWOT
  • Fig. 35 Latin America SWOT
  • Fig. 36 MEA SWOT
  • Fig. 37 North America, by country
  • Fig. 38 North America
  • Fig. 39 North America market estimates and forecasts, 2018 - 2030
  • Fig. 40 U.S.
  • Fig. 41 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 42 Canada
  • Fig. 43 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 44 Mexico
  • Fig. 45 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 46 Europe
  • Fig. 47 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 48 UK
  • Fig. 49 UK market estimates and forecasts, 2018 - 2030
  • Fig. 50 Germany
  • Fig. 51 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 52 France
  • Fig. 53 France market estimates and forecasts, 2018 - 2030
  • Fig. 54 Italy
  • Fig. 55 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 56 Spain
  • Fig. 57 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 58 Denmark
  • Fig. 59 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 60 Sweden
  • Fig. 61 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 62 Norway
  • Fig. 63 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 64 Asia Pacific
  • Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 66 China
  • Fig. 67 China market estimates and forecasts, 2018 - 2030
  • Fig. 68 Japan
  • Fig. 69 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 70 India
  • Fig. 71 India market estimates and forecasts, 2018 - 2030
  • Fig. 72 Singapore
  • Fig. 73 Singapore market estimates and forecasts, 2018 - 2030
  • Fig. 74 South Korea
  • Fig. 75 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 76 Australia
  • Fig. 77 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 78 Latin America
  • Fig. 79 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 80 Brazil
  • Fig. 81 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 82 Argentina
  • Fig. 83 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 84 Middle East and Africa
  • Fig. 85 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 86 South Africa
  • Fig. 87 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 88 Saudi Arabia
  • Fig. 89 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 90 UAE
  • Fig. 91 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 92 Kuwait
  • Fig. 93 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 94 Market share of key market companies - Breast Adenocarcinoma Treatment market